Bausch Health Companies' (BHC) "Hold" Rating Reaffirmed at Jefferies Financial Group

Bausch Health Companies (NYSE:BHC - Get Free Report)'s stock had its "hold" rating reiterated by equities research analysts at Jefferies Financial Group in a research report issued on Thursday, Marketbeat Ratings reports. They currently have a $8.00 target price on the stock, down from their prior target price of $12.00. Jefferies Financial Group's target price would indicate a potential upside of 26.68% from the company's current price.

A number of other analysts have also recently weighed in on the company. StockNews.com raised Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Friday, October 25th. Evercore ISI upgraded shares of Bausch Health Companies to a "hold" rating in a research report on Tuesday, October 15th. Finally, Royal Bank of Canada cut their price objective on shares of Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $7.42.

Bausch Health Companies Stock Down 2.1 %

BHC traded down $0.14 during trading on Thursday, hitting $6.32. 6,162,529 shares of the stock were exchanged, compared to its average volume of 3,379,447. Bausch Health Companies has a 1-year low of $3.96 and a 1-year high of $11.46. The stock has a fifty day moving average price of $7.62 and a two-hundred day moving average price of $7.46. The firm has a market capitalization of $2.28 billion, a P/E ratio of -13.16, a PEG ratio of 0.34 and a beta of 0.68.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BHC. Tobam grew its holdings in shares of Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after acquiring an additional 1,422 shares during the period. DGS Capital Management LLC purchased a new stake in Bausch Health Companies during the fourth quarter worth $143,000. Kendall Capital Management grew its holdings in Bausch Health Companies by 43.4% in the fourth quarter. Kendall Capital Management now owns 17,995 shares of the company's stock valued at $145,000 after purchasing an additional 5,445 shares during the last quarter. Principal Securities Inc. increased its position in shares of Bausch Health Companies by 39.7% in the fourth quarter. Principal Securities Inc. now owns 19,220 shares of the company's stock valued at $155,000 after buying an additional 5,464 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Bausch Health Companies during the 4th quarter worth $180,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.